Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Head-Zap device ease fibromyalgia pain at home?

NCT ID NCT07583056

Recruiting now Symptom relief Sponsor: Ionclinics & Deionic SL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests whether a high-dose version of a gentle brain-stimulation device (tDCS) can reduce pain and other symptoms in 250 people with fibromyalgia. Participants will use the device at home, either on the motor cortex or the prefrontal cortex, and researchers will compare results to a standard protocol. The goal is to find a convenient, non-drug option for symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) device
What this could lead to
If successful, this could offer a safe, non-drug way to manage fibromyalgia pain and fatigue at home, reducing reliance on medications.
What could go wrong
This is an early-stage trial testing a new high-dose schedule. The benefits may be small or no better than standard tDCS, and not everyone may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROMYALGIA (FM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fibromyalgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIBROMYALGIA (FM)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.